Global Neuraminidase Inhibitors Drug Market Strategy, Trends, Growth, Research and Forecast 2030

Global Neuraminidase Inhibitors Drug Market, Analysis, Size, Share, Trends, COVID-19 Impact, and Forecast 2023-2030, By Type, By Application, and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East and Africa)

Market intelx offers the report on â€œGlobal Neuraminidase Inhibitors Drug Marketâ€ Analysis and Forecast 2021-2028. The global Neuraminidase Inhibitors Drug market was valued at US$ XX Billion in 2022 and is projected to reach US$ XX Billion in 2030, representing an XX% compound annual growth rate (CAGR) during the forecast period (2023-2030).

The report defines, describes, and forecasts the Neuraminidase Inhibitors Drug market, by extensive segments and region. It covers a detailed qualitative and quantitative analysis and various important aspects of the market. These include an analysis of the market dynamics, market analysis, premium insights, COVID-19 impact, segment analysis, regional analysis, competitive landscape, and competitive profiles.

The global Neuraminidase Inhibitors Drug market report highlights different scenarios of the Neuraminidase Inhibitors Drug Market and offers a comprehensive analysis of historical data (2018-2022 and forecast data (2023-2030), providing a detailed study on driver, restrains, opportunities, challenges, and emerging trends. This report gives a holistic view on market potential, market dynamics, growth opportunities, segmental markets, geographic scenario, competitive analysis, and projections with a suitable set of methodologies and assumptions. The report also provides value chain analysis, PESTLE analysis, Impact analysis, and PORTERâ€™s analysis. Premium insights give you access to insights that include: top trends, key investment pockets, top strategies followed by key players, and access to a strategic research advisor.

This report will enable you to make better informed decisions and gain a future-proof advantage over your competitors, decode the future of market, access intelligence on new technologies, macroeconomic shifts & social trends, make informed business decisions in response to changes in market, revise business plans and react to shifting industry developments, understanding of changing market dynamics, and identify lucrative opportunities.

Research Particulars:
Revenue: USD Million
Base Year: 2022
Forecast Years: 2023-2030 (Forecast for further years (up to 2035) shall be provided upon request)
Historical Years: 2018-2021
Regions Covered: North America, Asia Pacific, Europe, Latin America, and Middle East & Africa
Countries Covered: US, Canada, Mexico, China, India, Japan, South Korea, Germany, United Kingdom, France, Spain, Italy, Brazil, Argentina, GCC, South Africa, and Others.
Market Analysis: Value Chain Analysis, Porters Analysis, Pestle Analysis, COVID-19 Impact Analysis, and Impact Analysis.

Research Methodology
This report provides in-depth qualitative and quantitative analyses of the Global Neuraminidase Inhibitors Drug Market. Deep analysis and research were done during the report preparation. We have collected key data related to the Global Neuraminidase Inhibitors Drug Market using multiple approaches. Various secondary sources were referred to for the identification and collection of information for this study. Secondary sources include annual reports, press releases, and investor presentations of companies, white papers, medical journals, certified publications, articles from recognized authors, gold standard and silver standard websites, directories, and databases. The primary sources were industry experts from the core and related industries. These include service providers, technology developers, standards and certification organizations, and organizations related to all segments of the value chain. Interviews were conducted with various primary respondents, including key industry participants, C-level executives of key market players, subject-matter experts (SMEs), and industry consultants, to obtain and verify critical qualitative and quantitative information.

Market engineering process (which includes calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation) was completed with extensive primary research and secondary research to verify and validate the critical numbers arrived at. In the entire market engineering process, both top-down and bottom-up approaches were extensively utilised along with several data triangulation methods to perform market sizing and market forecasting for the overall market segments and sub segments listed in this report.

Competitive Overview
The section highlights the key competitors in the market, with a focus on presenting an in-depth analysis on business strategies including merger & acquisitions, partnership/ agreement/ joint venture, business expansion, new product launches, and other developments. This chapter also provides an analysis on leading companies and their positioning and share analysis. Company profiles focusses on in-depth analysis into their product portfolio, financial overview, geographic presence, growth strategies, and SWOT Analysis.

Market Segmentation:
Market intelx provides an analysis of the key segment and each sub-segment of the global Neuraminidase Inhibitors Drug market, along with forecasts at the global, regional, and country levels from 2023-2030. This report has segmented the market based on:

Neuraminidase Inhibitors Drug Market By Type:
Oseltamivir
Zanamivir
Peramivir
Laninamivir

Neuraminidase Inhibitors Drug Market By Application:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others

Companies Profiles in the Report:
Roche, GSK, Gilead Sciences, Daiichi Sankyo

Regional Coverage
The regional analysis includes the in-depth analysis on North America, Asia Pacific, Europe, Latin America and the Middle East and Africa.
â€¢ North America
o US
o Canada
o Mexico
â€¢ Asia Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia Pacific
â€¢ Europe
o Germany
o UK
o France
o Spain
o Italy
o Rest of Europe
â€¢ Latin America
o Brazil
o Argentina
o Rest of the Latin America
â€¢ Middle East and Africa
o GCC
o South Africa
o Rest of the Middle East and Africa

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Neuraminidase Inhibitors Drug Revenue
1.4 Market Analysis by Type
1.4.1 Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Type: 2021 VS 2030
1.4.2 Type 1
1.4.3 Type 2
1.4.4 Type 3
1.4.5 Type 4
1.5 Market by Application
1.5.1 Global Neuraminidase Inhibitors Drug Market Share by Application: 2022-2030
1.5.2 Application 1
1.5.3 Application 2
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Neuraminidase Inhibitors Drug Market
1.8.1 Global Neuraminidase Inhibitors Drug Market Status and Outlook (2016-2030)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Neuraminidase Inhibitors Drug Production Capacity Market Share by Manufacturers (2016-2021)
2.2 Global Neuraminidase Inhibitors Drug Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Neuraminidase Inhibitors Drug Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Neuraminidase Inhibitors Drug Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Neuraminidase Inhibitors Drug Sales Volume Market Share by Region (2016-2021)
3.2 Global Neuraminidase Inhibitors Drug Sales Revenue Market Share by Region (2016-2021)
3.3 North America Neuraminidase Inhibitors Drug Sales Volume
3.3.1 North America Neuraminidase Inhibitors Drug Sales Volume Growth Rate (2016-2021)
3.3.2 North America Neuraminidase Inhibitors Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.4 East Asia Neuraminidase Inhibitors Drug Sales Volume
3.4.1 East Asia Neuraminidase Inhibitors Drug Sales Volume Growth Rate (2016-2021)
3.4.2 East Asia Neuraminidase Inhibitors Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.5 Europe Neuraminidase Inhibitors Drug Sales Volume (2016-2021)
3.5.1 Europe Neuraminidase Inhibitors Drug Sales Volume Growth Rate (2016-2021)
3.5.2 Europe Neuraminidase Inhibitors Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.6 South Asia Neuraminidase Inhibitors Drug Sales Volume (2016-2021)
3.6.1 South Asia Neuraminidase Inhibitors Drug Sales Volume Growth Rate (2016-2021)
3.6.2 South Asia Neuraminidase Inhibitors Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.7 Southeast Asia Neuraminidase Inhibitors Drug Sales Volume (2016-2021)
3.7.1 Southeast Asia Neuraminidase Inhibitors Drug Sales Volume Growth Rate (2016-2021)
3.7.2 Southeast Asia Neuraminidase Inhibitors Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.8 Middle East Neuraminidase Inhibitors Drug Sales Volume (2016-2021)
3.8.1 Middle East Neuraminidase Inhibitors Drug Sales Volume Growth Rate (2016-2021)
3.8.2 Middle East Neuraminidase Inhibitors Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.9 Africa Neuraminidase Inhibitors Drug Sales Volume (2016-2021)
3.9.1 Africa Neuraminidase Inhibitors Drug Sales Volume Growth Rate (2016-2021)
3.9.2 Africa Neuraminidase Inhibitors Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.10 Oceania Neuraminidase Inhibitors Drug Sales Volume (2016-2021)
3.10.1 Oceania Neuraminidase Inhibitors Drug Sales Volume Growth Rate (2016-2021)
3.10.2 Oceania Neuraminidase Inhibitors Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.11 South America Neuraminidase Inhibitors Drug Sales Volume (2016-2021)
3.11.1 South America Neuraminidase Inhibitors Drug Sales Volume Growth Rate (2016-2021)
3.11.2 South America Neuraminidase Inhibitors Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.12 Rest of the World Neuraminidase Inhibitors Drug Sales Volume (2016-2021)
3.12.1 Rest of the World Neuraminidase Inhibitors Drug Sales Volume Growth Rate (2016-2021)
3.12.2 Rest of the World Neuraminidase Inhibitors Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
4 North America
4.1 North America Neuraminidase Inhibitors Drug Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Neuraminidase Inhibitors Drug Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Neuraminidase Inhibitors Drug Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Neuraminidase Inhibitors Drug Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Neuraminidase Inhibitors Drug Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Neuraminidase Inhibitors Drug Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Neuraminidase Inhibitors Drug Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Neuraminidase Inhibitors Drug Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Neuraminidase Inhibitors Drug Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Neuraminidase Inhibitors Drug Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Neuraminidase Inhibitors Drug Sales Volume Market Share by Type (2016-2021)
14.2 Global Neuraminidase Inhibitors Drug Sales Revenue Market Share by Type (2016-2021)
14.3 Global Neuraminidase Inhibitors Drug Sales Price by Type (2016-2021)
15 Consumption Analysis by Application
15.1 Global Neuraminidase Inhibitors Drug Consumption Volume by Application (2016-2021)
15.2 Global Neuraminidase Inhibitors Drug Consumption Value by Application (2016-2021)
16 Company Profiles and Key Figures in Neuraminidase Inhibitors Drug Business
16.1 Company 1
16.1.1 Company 1 Company Profile
16.1.2 Company 1 Neuraminidase Inhibitors Drug Product Specification
16.1.3 Company 1 Neuraminidase Inhibitors Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.2 Company 2
16.2.1 Company 2 Company Profile
16.2.2 Company 2 Neuraminidase Inhibitors Drug Product Specification
16.2.3 Company 2 Neuraminidase Inhibitors Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.3 Company 3
16.3.1 Company 3 Company Profile
16.3.2 Company 3 Neuraminidase Inhibitors Drug Product Specification
16.3.3 Company 3 Neuraminidase Inhibitors Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.4 Company 4
16.4.1 Company 4 Company Profile
16.4.2 Company 4 Neuraminidase Inhibitors Drug Product Specification
16.4.3 Company 4 Neuraminidase Inhibitors Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.5 Company 5
16.5.1 Company 5 Company Profile
16.5.2 Company 5 Neuraminidase Inhibitors Drug Product Specification
16.5.3 Company 5 Neuraminidase Inhibitors Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.6 Company 6
16.6.1 Company 6 Company Profile
16.6.2 Company 6 Neuraminidase Inhibitors Drug Product Specification
16.6.3 Company 6 Neuraminidase Inhibitors Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.7 Company 7
16.7.1 Company 7 Company Profile
16.7.2 Company 7 Neuraminidase Inhibitors Drug Product Specification
16.7.3 Company 7 Neuraminidase Inhibitors Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.8 Company 8
16.8.1 Company 8 Company Profile
16.8.2 Company 8 Neuraminidase Inhibitors Drug Product Specification
16.8.3 Company 8 Neuraminidase Inhibitors Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.9 Company 9
16.9.1 Company 9 Company Profile
16.9.2 Company 9 Neuraminidase Inhibitors Drug Product Specification
16.9.3 Company 9 Neuraminidase Inhibitors Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
17 Neuraminidase Inhibitors Drug Manufacturing Cost Analysis
17.1 Neuraminidase Inhibitors Drug Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Neuraminidase Inhibitors Drug
17.4 Neuraminidase Inhibitors Drug Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Neuraminidase Inhibitors Drug Distributors List
18.3 Neuraminidase Inhibitors Drug Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Neuraminidase Inhibitors Drug (2022-2030)
20.2 Global Forecasted Revenue of Neuraminidase Inhibitors Drug (2022-2030)
20.3 Global Forecasted Price of Neuraminidase Inhibitors Drug (2016-2030)
20.4 Global Forecasted Production of Neuraminidase Inhibitors Drug by Region (2022-2030)
20.4.1 North America Neuraminidase Inhibitors Drug Production, Revenue Forecast (2022-2030)
20.4.2 East Asia Neuraminidase Inhibitors Drug Production, Revenue Forecast (2022-2030)
20.4.3 Europe Neuraminidase Inhibitors Drug Production, Revenue Forecast (2022-2030)
20.4.4 South Asia Neuraminidase Inhibitors Drug Production, Revenue Forecast (2022-2030)
20.4.5 Southeast Asia Neuraminidase Inhibitors Drug Production, Revenue Forecast (2022-2030)
20.4.6 Middle East Neuraminidase Inhibitors Drug Production, Revenue Forecast (2022-2030)
20.4.7 Africa Neuraminidase Inhibitors Drug Production, Revenue Forecast (2022-2030)
20.4.8 Oceania Neuraminidase Inhibitors Drug Production, Revenue Forecast (2022-2030)
20.4.9 South America Neuraminidase Inhibitors Drug Production, Revenue Forecast (2022-2030)
20.4.10 Rest of the World Neuraminidase Inhibitors Drug Production, Revenue Forecast (2022-2030)
20.5 Forecast by Type and by Application (2022-2030)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2022-2030)
20.5.2 Global Forecasted Consumption of Neuraminidase Inhibitors Drug by Application (2022-2030)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Neuraminidase Inhibitors Drug by Country
21.2 East Asia Market Forecasted Consumption of Neuraminidase Inhibitors Drug by Country
21.3 Europe Market Forecasted Consumption of Neuraminidase Inhibitors Drug by Countriy
21.4 South Asia Forecasted Consumption of Neuraminidase Inhibitors Drug by Country
21.5 Southeast Asia Forecasted Consumption of Neuraminidase Inhibitors Drug by Country
21.6 Middle East Forecasted Consumption of Neuraminidase Inhibitors Drug by Country
21.7 Africa Forecasted Consumption of Neuraminidase Inhibitors Drug by Country
21.8 Oceania Forecasted Consumption of Neuraminidase Inhibitors Drug by Country
21.9 South America Forecasted Consumption of Neuraminidase Inhibitors Drug by Country
21.10 Rest of the world Forecasted Consumption of Neuraminidase Inhibitors Drug by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer

Research Methodology

Global Neuraminidase Inhibitors Drug Market Strategy, Trends, Growth, Research and Forecast 2030

Frequently Asked Questions

Select Licence Type

Connect with our sales team

Why Market Intelx

100%

24x7+

200+

80%

100%

1000+

Industries

News Room

Supports

Services

Office Addresses